Literature DB >> 32840579

COVID-19 and chronic renal disease: clinical characteristics and prognosis.

D Yang1,2, Y Xiao3, J Chen4, Y Chen1, P Luo5, Q Liu5, C Yang1, M Xiong1, Y Zhang1, X Liu1, H Chen1, A Deng4, K Huang1,2, B Cheng4, A Peng5.   

Abstract

BACKGROUND: Patients on dialysis were susceptible to coronavirus disease 2019 (COVID-19) and were prone to severe clinical characteristics after infection; acute kidney injury was related to mortality in COVID-19 cases. Limited is known about the characteristics of COVID-19 patients with end-stage renal disease not requiring renal replacement therapy (RRT). AIM: Evaluate clinical characteristics, course and outcomes of COVID-19 patients with chronic kidney disease (CKD) who did not require RRT and those on dialysis.
DESIGN: A two-center retrospective study.
METHODS: A total of 836 adult patients with COVID-19 (24 CKD not on dialysis; 15 dialysis-dependent CKD) were included. The study includes no patients with renal transplantation. Risk factors were explored.
RESULTS: CKD not requiring RRT is an independent risk factor for in-hospital death [adjusted odds ratio (aOR) 7.35 (95% CI 2.41-22.44)] and poor prognosis [aOR 3.01 (95% CI 1.23-7.33)]. Compared with COVID-19 cases without CKD, those with CKD not requiring RRT showed similar percentage of initial moderate cases (75.00% vs. 73.65%) but higher incidence of in-hospital neutrophilia (50.00% vs. 27.30%) or death (50.00% vs. 9.03%). The odds ratio of dialysis associated to mortality in CKD patients was 2.00 (95% CI 0.52-7.63), suggesting COVID-19 patients with dialysis-dependent CKD were at greater risk of in-hospital death. For COVID-19 patients with CKD not requiring RRT, statins reduced the risk of neutrophilia [OR 0.10 (95% CI 0.01-0.69)] while diuretics increased the risk of neutrophilia [OR 15.4 (95% CI 1.47-160.97)], although both showed no association to mortality.
CONCLUSION: COVID-19 patients with CKD presented high incidence of neutrophilia, poor prognosis and in-hospital death, with dialysis patients being more vulnerable.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2020        PMID: 32840579      PMCID: PMC7499788          DOI: 10.1093/qjmed/hcaa258

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  18 in total

1.  Clinical Features and Outcome of Stroke with COVID-19. COVID-19 Stroke Study Group (CSSG), India.

Authors:  Rohit Bhatia; M V Padma Srivastava; P N Sylaja; Snigdha Komakula; Ashish Upadhyay; Vibhor Pardasani; Thomas Iype; Rajsrinivas Parthasarathy; Rajshekhar Reddy; Suman Kushwaha; Jayanta Roy; P Satish; Anjan Trikha; Naveet Wig; Lalit Dhar; Deepti Vibha; Venugopalan Y Vishnu; Awadh Kishore Pandit; Anu Gupta; A Elavarasi; Ayush Agarwal; Vipul Gupta; Rakesh K Singh; Harsh Oza; Hiral Halani; Dileep Ramachandran; Githin B George; Praveen Panicker; M K Suresh; S Kumaravelu; Dheeraj Khurana; Srijithesh P Rajendran; Vijaya Pamidimukkala; Salil Gupta; Jeyaraj D Pandian; Debashish Chowdhury; Nirendra K Rai; Arvind Sharma; Vivek K Nambiar
Journal:  Ann Indian Acad Neurol       Date:  2021-08-30       Impact factor: 1.383

2.  Epidemiological Characteristics and Mortality Risk Factors Comparison in Dialysis and Non-Dialysis CKD Patients with COVID-19-A Single Center Experience.

Authors:  Andrei Niculae; Ileana Peride; Ana-Maria Nechita; Lucian Cristian Petcu; Mirela Tiglis; Ionel Alexandru Checherita
Journal:  J Pers Med       Date:  2022-06-13

Review 3.  Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Abraham Degarege; Zaeema Naveed; Josiane Kabayundo; David Brett-Major
Journal:  Pathogens       Date:  2022-05-10

Review 4.  Biological Actions, Implications, and Cautions of Statins Therapy in COVID-19.

Authors:  Chengyu Liu; Wanyao Yan; Jiajian Shi; Shun Wang; Anlin Peng; Yuchen Chen; Kun Huang
Journal:  Front Nutr       Date:  2022-06-22

5.  Characteristics and outcomes of hemodialysis patients with COVID-19: a retrospective single center study.

Authors:  Yongwen Luo; Junli Li; Zhifen Liu; Heping Yu; Xiang Peng; Cheng'an Cao
Journal:  PeerJ       Date:  2020-11-26       Impact factor: 2.984

6.  Statins in patients with COVID-19: a retrospective cohort study in Iranian COVID-19 patients.

Authors:  Payam Peymani; Tania Dehesh; Pooneh Mokarram; Saeid Ghavami; Farnaz Aligolighasemabadi; Mohammadamin Sadeghdoust; Katarzyna Kotfis; Mazaher Ahmadi; Parvaneh Mehrbod; Pooya Iranpour; Sanaz Dastghaib; Ahmad Nasimian; Amir Ravandi; Biniam Kidane; Naseer Ahmed; Pawan Sharma; Shahla Shojaei; Kamran Bagheri Lankarani; Andrzej Madej; Nima Rezaei; Tayyebeh Madrakian; Marek J Los; Hagar Ibrahim Labouta
Journal:  Transl Med Commun       Date:  2021-01-25

Review 7.  Myocardial Involvement in COVID-19: an Interaction Between Comorbidities and Heart Failure with Preserved Ejection Fraction. A Further Indication of the Role of Inflammation.

Authors:  Gregorio Zaccone; Daniela Tomasoni; Leonardo Italia; Carlo Mario Lombardi; Marco Metra
Journal:  Curr Heart Fail Rep       Date:  2021-04-22

8.  COVID-19 booster vaccination and dialysis patients.

Authors: 
Journal:  QJM       Date:  2021-11-05

9.  Impact of Kidney Failure on the Severity of COVID-19.

Authors:  Dorota Zarębska-Michaluk; Jerzy Jaroszewicz; Magdalena Rogalska; Beata Lorenc; Marta Rorat; Anna Szymanek-Pasternak; Anna Piekarska; Aleksandra Berkan-Kawińska; Katarzyna Sikorska; Magdalena Tudrujek-Zdunek; Barbara Oczko-Grzesik; Beata Bolewska; Piotr Czupryna; Dorota Kozielewicz; Justyna Kowalska; Regina Podlasin; Krzysztof Kłos; Włodzimierz Mazur; Piotr Leszczyński; Bartosz Szetela; Katarzyna Reczko; Robert Flisiak
Journal:  J Clin Med       Date:  2021-05-10       Impact factor: 4.241

10.  The use of statins was associated with reduced COVID-19 mortality: a systematic review and meta-analysis.

Authors:  Kuan-Sheng Wu; Pei-Chin Lin; Yao-Shen Chen; Tzu-Cheng Pan; Pei-Ling Tang
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.